Biogen Escapes Class Action Over PBMs, Generic Drug Entry Plan

Biogen Inc. notched a win in a legal battle over whether it unlawfully orchestrated a scheme working with the nation’s largest pharmacy benefit managers to impair competition from generic versions of its brand-name drug Tecfidera.

Judge April Perry of the US District Court for the Northern District of Illinois tossed a class action by the city of Baltimore and sponsors of employee health plans on Wednesday because their allegations fail to adequately plead cognizable antitrust claims and lack directness between themselves and the injuries allegedly suffered.

Nowhere do plaintiffs “allege that they used the services of any co-conspiring PBMs or ...